Horizon 3 Healthcare
VC Fund
Melbourne, Australia
Horizon 3 Healthcare is a VC fund in Melbourne focused on Health Care and Medical Device. H3 Healthcare focuses on investing in growth-stage healthcare companies that have achieved clinical validation and are generating revenue.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Horizon 3 Healthcare invests in
Stages Horizon 3 Healthcare invests in
Countries Horizon 3 Healthcare invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 2 (100%)
- Medical Device 2 (100%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
Stage
- Series E 1 (50%)
- Venture - Series Unknown 1 (50%)
Country
- Switzerland 1 (50%)
- United States 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Matt McNamara
CIO & Director
|
CIO & Director | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Xeltis
|
A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for whichclinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. | $23.3M / Venture - Series Unknown / Jul 28, 2026 | |
Cardiac Dimensions
|
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $53M / Series E / Mar 20, 2025 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Horizon 3 Healthcare invest in?
Horizon 3 Healthcare invests primarily in Health Care, Medical Device and Therapeutics startups, most often at Series E and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Horizon 3 Healthcare?
Public channels for Horizon 3 Healthcare include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Horizon 3 Healthcare?
The team at Horizon 3 Healthcare includes Matt McNamara (CIO & Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
